For example, SGLT2 inhibition modulates renal lipid metabolism in db/db mice (Wang et al., 2017), ameliorates obesity in high-fat diet-fed animal models by improving FAO (Wei et al., 2020; Yokono et al., 2014), and reduces the cardiotoxic lipids in the hearts of diabetic fatty rats (Aragón-Herrera et al., 2019). This evidence concerns the gene SLC5A2 and obesity disorder.